title: Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors.
abstract: The median age at diagnosis of chronic myeloid leukemia (CML) is between 60 and 65 years in most epidemiologic registries. Rather than age per se, a comprehensive evaluation of comorbidities may describe more properly the general clinical status of a patient. Tyrosine-kinase inhibitors (TKIs) have a different tolerability profile, and some adverse events (AEs) are peculiar of each drug, in particular, in presence of predisposing factors (comorbidities, concomitant medications). This article will review the impact of comorbidities in the safety and outcome of CML patients treated with TKIs. We will explore how the comorbidity status may be considered, together with CML-related factors, in the selection of the TKI in order to optimize treatment.
authors.affiliation: Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Institute of Hematology "L. e A. Seragnòli", Bologna, Italy.
authors.forename: Gabriele
authors.initials: G
authors.lastname: Gugliotta
authors.forename: Fausto
authors.initials: F
authors.lastname: Castagnetti
authors.forename: Miriam
authors.initials: M
authors.lastname: Fogli
authors.forename: Michele
authors.initials: M
authors.lastname: Cavo
authors.forename: Michele
authors.initials: M
authors.lastname: Baccarani
authors.forename: Gianantonio
authors.initials: G
authors.lastname: Rosti
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015897:Comorbidity; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors